Fairvalue-Calculator Fairvalue-Calculator
EN DE

Optipharm.CO.,LTD (153710) Fair Value & Analysis

Healthcare · KR · Market cap 67.8B KRW

Price4,480 KRW
Fair Value7,792 KRW
Upside+73.9%
Quality95/100
Evidence: Low Range 5,844 KRW – 9,739 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Optipharm.CO.,LTD (153710) currently trades at 4,480 KRW, while our model-based Fair Value estimate is 7,792 KRW — implying the stock looks roughly 73.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and changed its name to Optipharm.CO.,LTD in 2012. Optipharm.CO.,LTD was founded in 2000 and is based in Cheongju, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Optipharm.CO.,LTD (153710) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 7,792 KRW versus a price of 4,480 KRW — about +74% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 153710?
Our 21-model fair value for Optipharm.CO.,LTD is 7,792 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 4,480 KRW.
What is the quality score of 153710?
Optipharm.CO.,LTD has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.